EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer

Aim: Innate resistance to the CHK1 inhibitor prexasertib has been described, but resistance mechanisms are not understood. We aimed to determine the role epidermal growth factor receptor (EGFR) plays in innate resistance to prexasertib in triple negative breast cancer (TNBC). Methods: Using a panel...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kevin J., Wright, Griffin, Bryant, Hannah, Wiggins, Leigh Ann, Schuler, Michele, Gassman, Natalie R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992551/
https://www.ncbi.nlm.nih.gov/pubmed/35582228
http://dx.doi.org/10.20517/cdr.2020.73

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992551/
https://www.ncbi.nlm.nih.gov/pubmed/35582228
http://dx.doi.org/10.20517/cdr.2020.73

Ejemplares similares